BioCatalystWatch
MAZEWorkspace / MAZE / OverviewCompany library
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE)

Website

Price
Market cap
Next catalystExpected 1H 2027MZE782 — planned CKD proof-of-concept trial · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

MZE782

SLC6A19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

MZE782

SLC6A19

PreINDP1P3FilingApproved
Upcoming / outlook

MZE829

APOL1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

MZE782

SLC6A19

PreINDP1P3FilingApproved
Upcoming / outlook

MZE782

SLC6A19

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

MZE829

APOL1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Partner / License out

UNC13A

UNC13A

GYS1

PreINDP1P2P3FilingApproved

History / paused

GYS1

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

MAZE PR & News

PR & News

MAZE SEC archive